Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 7537

BillFederalHouseIn Committee
Infectious Disease Therapies Research and Innovation Act of 2020
About This Bill
Committee
Latest Action · July 9, 2020
Referred to the House Committee on Ways and Means.
Congress
116th (2019–2021)
Introduced
July 9, 2020
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Infectious Disease Therapies Research and Innovation Act of 2020 This bill exempts from the definition of passive activity, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.